Mikhail Blagosklonny Talks about Rapamycin

In the recent past, most people believed that aging was a functional decline occasioned by the buildup of indiscriminate molecular damage. They were of the opinion that it could not be prevented. The hyperfunction theory played a pivotal role in breaking this dogma. It described aging as the ongoing growth enhanced by signaling pathways like TOR (Target of Rapamycin). Notably, TOR-centric model is used to predict the rapamycin that can be beneficial to humans in terms of treating aging and preventing diseases. According to the article, “Rejuvenating immunity: “anti-aging drug today” eight years later,” Mikhail Blagosklonny posits that rapamycin can be used to prolong the life of a patient. Read more about Mikhail at LinkedIn

When used in proper schedules and doses, rapamycin and different rapalogs can be integral in enhancing the lifespan of humans. Most anonymous peer-reviewers and opponents ridiculed the theory. Mikhail posited that in 2008, predications indicated that five years later, the existing opponents of the theory would despise TOR-centric model. Recently, a study on Evirolimus (RAD001), which is an analog of rapamycin, made sensational headlines as it proved to improve the immunity of aging persons. Mikhail Blagosklonny posits that there could be the possibility that researchers are working on a “fountain of youth” drug that can enhance the health of older people and delay the outcomes of aging.

In 2006, Rapamune or Sirolimus, was approved to be used in the clinics. Mikhail posits that all aging-related diseases such as Alzheimer, osteoporosis, metabolic disorders, autoimmunity, cardiovascular diseases and cancer can be treated using rapamycin. He added that the drug would rank as the most useful anti-aging drug to prevent various diseases and slow down senescence. Mikhail contends that rapamycin is safe and can be administered on a daily basis to transplant patients for more than a year. Its pharmacokinetics have been researched properly. It has been found that rapamycin transforms the immunity of the users from aged-type to infant-type. To this end, it rejuvenates the immunity. This means that it does away with hyper-immunity instead of suppressing immunity.

Mikhail says that the well tolerated and non-toxic drug is safe for everyday oral administration. Clinical and preclinical data shows that rapamycin seems to have calorie-restriction-mimicking, bone-sparing and anti-tumor side effects. The drug has certain immunostimulatory activities. Many researchers have studied the drug and confirmed that it will become the pillars of anti-aging therapy in recent years. Until 2014, all studies showed that rapamycin would not be viable owing to its side effects. In addition, the use of the drug in this generation was considered fiction. Mikhail posits that rapamycin will be used in our lifetime. This information was originally mentioned on Impact Journals as highlighted in the following link https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637294/

About Mikhail Blagosklonny

Mikhail is a renowned professor of oncology at the renowned cancer institute, Roswell Park. He is a graduate of the celebrated First Pavlov State Medical University of St. Petersburg. He has rendered his professional services at New York Medical College and Ordway Research Institute. His research focuses on anti-aging drugs, targeted cancer therapies, cancer and Biogerontology. Blagosklonny serves as an editor for Cell Cycle and Oncotarget. He loves to study about molecular and cellular biology, signal transduction, selective protection, cell cycle, mitosis and drug resistance for normal cells.

Learn more: https://www.ncbi.nlm.nih.gov/pubmed/?term=blagosklonny